Want to join the conversation?
$BIIB 2Q15 Call: In July 2015, BIIB presented additional interim aducanumab Phase 1b study at the Alzheimer’s Association International Conference. Finalized the aducanumab Phase 3 study design; program will be conducted globally and will include more than 300 sites. Obtained Phase 2 study results for TYSABRI.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.